Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Oct 1;100(7):1863–1869. doi: 10.1172/JCI119715

Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling.

P Peraldi 1, M Xu 1, B M Spiegelman 1
PMCID: PMC508373  PMID: 9312188

Abstract

TNF-alpha has been shown to be an important mediator of insulin resistance linked to obesity. This cytokine induces insulin resistance, at least in part, through inhibition of the tyrosine kinase activity of the insulin receptor. Recently, a new class of compounds, the antidiabetic thiazolidinediones (TZDs), has been shown to improve insulin resistance in obesity and non-insulin-dependent diabetes mellitus in both rodents and man. Here we show that TZDs have powerful effects on the ability of TNF-alpha to alter the most proximal steps of insulin signaling, including tyrosine phosphorylation of the insulin receptor and its major substrate, IRS-1, and activation of PI3-kinase. Troglitazone or pioglitazone essentially eliminate the reduction in tyrosine phosphorylation of IR and IRS-1 caused by TNF-alpha in fat cells, even at relatively high doses (25 ng/ml). That this effect of TZDs operates through activation of the nuclear receptor PPARgamma/ RXR complex is shown by the fact that similar effects are observed with other PPARgamma/RXR ligands such as 15 deoxy Delta12,14PGJ2 and LG268. The TZDs do not inhibit all TNF-alpha signaling in that the transcription factor NF-kB is still induced well. These data indicate that TZDs can specifically block certain actions of TNF-alpha related to insulin resistance, suggesting that this block may contribute to their antidiabetic actions.

Full Text

The Full Text of this article is available as a PDF (264.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boehm M. F., Zhang L., Zhi L., McClurg M. R., Berger E., Wagoner M., Mais D. E., Suto C. M., Davies J. A., Heyman R. A. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem. 1995 Aug 4;38(16):3146–3155. doi: 10.1021/jm00016a018. [DOI] [PubMed] [Google Scholar]
  2. De Vos P., Lefebvre A. M., Miller S. G., Guerre-Millo M., Wong K., Saladin R., Hamann L. G., Staels B., Briggs M. R., Auwerx J. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest. 1996 Aug 15;98(4):1004–1009. doi: 10.1172/JCI118860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Feinstein R., Kanety H., Papa M. Z., Lunenfeld B., Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993 Dec 15;268(35):26055–26058. [PubMed] [Google Scholar]
  4. Forman B. M., Tontonoz P., Chen J., Brun R. P., Spiegelman B. M., Evans R. M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995 Dec 1;83(5):803–812. doi: 10.1016/0092-8674(95)90193-0. [DOI] [PubMed] [Google Scholar]
  5. Garcia de Herreros A., Birnbaum M. J. The acquisition of increased insulin-responsive hexose transport in 3T3-L1 adipocytes correlates with expression of a novel transporter gene. J Biol Chem. 1989 Nov 25;264(33):19994–19999. [PubMed] [Google Scholar]
  6. Hamann A., Benecke H., Le Marchand-Brustel Y., Susulic V. S., Lowell B. B., Flier J. S. Characterization of insulin resistance and NIDDM in transgenic mice with reduced brown fat. Diabetes. 1995 Nov;44(11):1266–1273. doi: 10.2337/diab.44.11.1266. [DOI] [PubMed] [Google Scholar]
  7. Hofmann C., Lorenz K., Braithwaite S. S., Colca J. R., Palazuk B. J., Hotamisligil G. S., Spiegelman B. M. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 1994 Jan;134(1):264–270. doi: 10.1210/endo.134.1.8275942. [DOI] [PubMed] [Google Scholar]
  8. Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995 May;95(5):2409–2415. doi: 10.1172/JCI117936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hotamisligil G. S., Budavari A., Murray D., Spiegelman B. M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest. 1994 Oct;94(4):1543–1549. doi: 10.1172/JCI117495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hotamisligil G. S., Murray D. L., Choy L. N., Spiegelman B. M. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4854–4858. doi: 10.1073/pnas.91.11.4854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hotamisligil G. S., Peraldi P., Budavari A., Ellis R., White M. F., Spiegelman B. M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996 Feb 2;271(5249):665–668. doi: 10.1126/science.271.5249.665. [DOI] [PubMed] [Google Scholar]
  12. Hotamisligil G. S., Shargill N. S., Spiegelman B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87–91. doi: 10.1126/science.7678183. [DOI] [PubMed] [Google Scholar]
  13. Iwamoto Y., Kuzuya T., Matsuda A., Awata T., Kumakura S., Inooka G., Shiraishi I. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991 Nov;14(11):1083–1086. doi: 10.2337/diacare.14.11.1083. [DOI] [PubMed] [Google Scholar]
  14. Iwanishi M., Kobayashi M. Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Metabolism. 1993 Aug;42(8):1017–1021. doi: 10.1016/0026-0495(93)90016-h. [DOI] [PubMed] [Google Scholar]
  15. Kern P. A., Saghizadeh M., Ong J. M., Bosch R. J., Deem R., Simsolo R. B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995 May;95(5):2111–2119. doi: 10.1172/JCI117899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kliewer S. A., Lenhard J. M., Willson T. M., Patel I., Morris D. C., Lehmann J. M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995 Dec 1;83(5):813–819. doi: 10.1016/0092-8674(95)90194-9. [DOI] [PubMed] [Google Scholar]
  17. Kobayashi M., Iwanishi M., Egawa K., Shigeta Y. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes. 1992 Apr;41(4):476–483. doi: 10.2337/diab.41.4.476. [DOI] [PubMed] [Google Scholar]
  18. Kreutter D. K., Andrews K. M., Gibbs E. M., Hutson N. J., Stevenson R. W. Insulinlike activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes. Diabetes. 1990 Nov;39(11):1414–1419. doi: 10.2337/diab.39.11.1414. [DOI] [PubMed] [Google Scholar]
  19. Kroder G., Bossenmaier B., Kellerer M., Capp E., Stoyanov B., Mühlhöfer A., Berti L., Horikoshi H., Ullrich A., Häring H. Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J Clin Invest. 1996 Mar 15;97(6):1471–1477. doi: 10.1172/JCI118569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953–12956. doi: 10.1074/jbc.270.22.12953. [DOI] [PubMed] [Google Scholar]
  21. Maegawa H., Ide R., Hasegawa M., Ugi S., Egawa K., Iwanishi M., Kikkawa R., Shigeta Y., Kashiwagi A. Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities. J Biol Chem. 1995 Mar 31;270(13):7724–7730. doi: 10.1074/jbc.270.13.7724. [DOI] [PubMed] [Google Scholar]
  22. Martin S. S., Haruta T., Morris A. J., Klippel A., Williams L. T., Olefsky J. M. Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3-L1 adipocytes. J Biol Chem. 1996 Jul 26;271(30):17605–17608. doi: 10.1074/jbc.271.30.17605. [DOI] [PubMed] [Google Scholar]
  23. Mukherjee R., Davies P. J., Crombie D. L., Bischoff E. D., Cesario R. M., Jow L., Hamann L. G., Boehm M. F., Mondon C. E., Nadzan A. M. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 1997 Mar 27;386(6623):407–410. doi: 10.1038/386407a0. [DOI] [PubMed] [Google Scholar]
  24. Nolan J. J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994 Nov 3;331(18):1188–1193. doi: 10.1056/NEJM199411033311803. [DOI] [PubMed] [Google Scholar]
  25. Nolan J. J., Olefsky J. M., Nyce M. R., Considine R. V., Caro J. F. Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes. 1996 Sep;45(9):1276–1278. doi: 10.2337/diab.45.9.1276. [DOI] [PubMed] [Google Scholar]
  26. Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 1996 Jul;45(7):881–885. doi: 10.2337/diab.45.7.881. [DOI] [PubMed] [Google Scholar]
  27. Ohsumi J., Sakakibara S., Yamaguchi J., Miyadai K., Yoshioka S., Fujiwara T., Horikoshi H., Serizawa N. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology. 1994 Nov;135(5):2279–2282. doi: 10.1210/endo.135.5.7956951. [DOI] [PubMed] [Google Scholar]
  28. Okada T., Kawano Y., Sakakibara T., Hazeki O., Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem. 1994 Feb 4;269(5):3568–3573. [PubMed] [Google Scholar]
  29. Peraldi P., Hotamisligil G. S., Buurman W. A., White M. F., Spiegelman B. M. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem. 1996 May 31;271(22):13018–13022. doi: 10.1074/jbc.271.22.13018. [DOI] [PubMed] [Google Scholar]
  30. Randle P. J., Newsholme E. A., Garland P. B. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J. 1964 Dec;93(3):652–665. doi: 10.1042/bj0930652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Saghizadeh M., Ong J. M., Garvey W. T., Henry R. R., Kern P. A. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996 Feb 15;97(4):1111–1116. doi: 10.1172/JCI118504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Saltiel A. R., Olefsky J. M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996 Dec;45(12):1661–1669. doi: 10.2337/diab.45.12.1661. [DOI] [PubMed] [Google Scholar]
  33. Sandouk T., Reda D., Hofmann C. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology. 1993 Jul;133(1):352–359. doi: 10.1210/endo.133.1.8319581. [DOI] [PubMed] [Google Scholar]
  34. Spiegelman B. M., Flier J. S. Adipogenesis and obesity: rounding out the big picture. Cell. 1996 Nov 1;87(3):377–389. doi: 10.1016/s0092-8674(00)81359-8. [DOI] [PubMed] [Google Scholar]
  35. Stephens J. M., Pekala P. H. Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J Biol Chem. 1992 Jul 5;267(19):13580–13584. [PubMed] [Google Scholar]
  36. Stevenson R. W., McPherson R. K., Genereux P. E., Danbury B. H., Kreutter D. K. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism. 1991 Dec;40(12):1268–1274. doi: 10.1016/0026-0495(91)90027-t. [DOI] [PubMed] [Google Scholar]
  37. Suter S. L., Nolan J. J., Wallace P., Gumbiner B., Olefsky J. M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992 Feb;15(2):193–203. doi: 10.2337/diacare.15.2.193. [DOI] [PubMed] [Google Scholar]
  38. Szalkowski D., White-Carrington S., Berger J., Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 1995 Apr;136(4):1474–1481. doi: 10.1210/endo.136.4.7895657. [DOI] [PubMed] [Google Scholar]
  39. Tanti J. F., Grémeaux T., Grillo S., Calleja V., Klippel A., Williams L. T., Van Obberghen E., Le Marchand-Brustel Y. Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocation in adipocytes. J Biol Chem. 1996 Oct 11;271(41):25227–25232. doi: 10.1074/jbc.271.41.25227. [DOI] [PubMed] [Google Scholar]
  40. Tominaga M., Igarashi M., Daimon M., Eguchi H., Matsumoto M., Sekikawa A., Yamatani K., Sasaki H. Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J. 1993 Jun;40(3):343–349. doi: 10.1507/endocrj.40.343. [DOI] [PubMed] [Google Scholar]
  41. Tontonoz P., Hu E., Spiegelman B. M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994 Dec 30;79(7):1147–1156. doi: 10.1016/0092-8674(94)90006-x. [DOI] [PubMed] [Google Scholar]
  42. Van Obberghen E., Ksauga M., Le Cam A., Hedo J. A., Itin A., Harrison L. C. Biosynthetic labeling of insulin receptor: studies of subunits in cultured human IM-9 lymphocytes. Proc Natl Acad Sci U S A. 1981 Feb;78(2):1052–1056. doi: 10.1073/pnas.78.2.1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Young P. W., Cawthorne M. A., Coyle P. J., Holder J. C., Holman G. D., Kozka I. J., Kirkham D. M., Lister C. A., Smith S. A. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes. 1995 Sep;44(9):1087–1092. doi: 10.2337/diab.44.9.1087. [DOI] [PubMed] [Google Scholar]
  44. Zhang B., Graziano M. P., Doebber T. W., Leibowitz M. D., White-Carrington S., Szalkowski D. M., Hey P. J., Wu M., Cullinan C. A., Bailey P. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem. 1996 Apr 19;271(16):9455–9459. doi: 10.1074/jbc.271.16.9455. [DOI] [PubMed] [Google Scholar]
  45. Zhang B., Szalkowski D., Diaz E., Hayes N., Smith R., Berger J. Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes. J Biol Chem. 1994 Oct 14;269(41):25735–25741. [PubMed] [Google Scholar]
  46. el-Kebbi I. M., Roser S., Pollet R. J. Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism. 1994 Aug;43(8):953–958. doi: 10.1016/0026-0495(94)90173-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES